Test your ideas in Turbine's digital lab

Turbine

Simulated Cell™ augments your pipeline through multiple products and solutions

TARGET SELECTION
Turbine uncovers novel targets to expand your pipeline
Contact us Read more

    Close

    ADC PAYLOADS
    Turbine simulates payloads to match your ADC to the right patients
    Contact us Read more

      Close

      CLINICAL POSITIONING
      Turbine identifies the best responder patients for your programs
      Contact us Read more

        Close

        DDR
        Turbine unlocks the commercial potential of your DDRi
        Contact us Read more

          Close

            Close

            Scientists have more ideas than ever - our simulation platform helps pick the right ones

            Data science-augmented R&D

            Many hypotheses. Hard to pick.

            Simulation-aided R&D

            Decision engine to select best ideas
            Simulations let you design more experiments to get a more comprehensive answer

            50M+ experiments / day

            • Engineer any sample to simulate
            • Test all relevant perturbations
            moreless
            Simulations are a mechanism engine, showing "why" something occurs

            Mechanistic hypotheses lead to a 50% higher likelihood of validation

            • Select experiments based on mechanistic readouts from our translational toolkit
            • Fail wrong ideas early with Turbine’s in-house validation assays
            moreless
            Simulations base every decision on evidence, boosting PoS

            2x faster timeline from scientific question to validation

            • Integrate pharma knowledge
            • Fit into existing processes
            moreless
            Drag / scroll horizontally for more

            R&D is full of choices - we helped partners make the right ones, repeatedly

            TARGET
            DISCOVERY
            COMBINATION
            DESIGN
            BIOMARKER
            SELECTION
            DISEASE
            POSITIONING
            DRUG
            PHARMACOLOGY
            INDICATION
            EXPANSION
            Impact

            Simulations have shown impact in various programs, at multiple stages of R&D


            APPLICATION AREAS
             
            TARGET
            DISCOVERY
            DRUG
            DISCOVERY

            PRECLINICAL
            EARLY
            DEVELOPMENT
            DEVELOPMENT AND
            COMMERCIALIZATION
            TARGET DISCOVERY
            LATEST NEWS
            TARGET DISCOVERY
            LIG4
            TARGET DISCOVERY
            NEK1
            BIOMARKER SELECTION
            BIOMARKER SELECTION
            DISEASE POSITIONING
            CDC7
            COMBINATION DESIGN
            WEE1
            BIOMARKER SELECTION
            COMBINATION DESIGN
            BIOMARKER SELECTION
            DISEASE POSITIONING
            Top pharma partner
            COMBINATION DESIGN
            DISEASE POSITIONING
            PUBLICATION
            Clear Filters

            Results you can trust quickly delivered, seamlessly integrated into your workflow

            Results you can trust quickly delivered, seamlessly integrated into your workflow Results you can trust quickly delivered, seamlessly integrated into your workflow
            Contact us
            DAVID M. RUBIN PhD
            Managing Director of MSD Global Health Innovation Fund
            “We believe Turbine’s Simulated Cell has the potential to transform key aspects of the oncology drug discovery and development process, providing insight at scale that will shed light on even the most challenging biological mechanisms.”
            ALAN BARGE
            ex VP and Head of Oncology and Infection at AstraZeneca
            “Turbine can fundamentally change the way in which novel targets in precision oncology are identified.”
            TOM LOUNIBOS
            Global Managing Director of Accenture Ventures
            "Turbine’s AI-based platform has clearly demonstrated the ability to unlock high-quality biological insights for our clients across the biopharma industry."

            PARTNERS AND INVESTORS

              Close